Persistent Depressive Disorder

Continuing Education Activity

Persistent depressive disorder (PDD), as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), merges the previous diagnoses of dysthymic disorder and chronic major depressive disorder. This condition is marked by a depressed mood lasting most of the day, for more days than not, over at least 2 years in adults or 1 year in children and adolescents. PDD can begin early in life and often becomes chronic, with symptoms that persist or fluctuate but never completely resolve. Individuals with PDD face a heightened risk of suicidal thoughts and behaviors, with functional impairments that can be as severe as or more severe than those experienced in major depressive disorder.

The educational activity provides healthcare professionals with a comprehensive understanding of PDD's neurobiology, treatment modalities, and the critical role of interprofessional collaboration. Interprofessional teams bring diverse expertise and perspectives, leading to more accurate diagnoses, holistic treatment plans, and improved overall care for individuals with PDD.

Objectives:

• Assess individuals for persistent depressive disorder based on history and physical examination.
• Identify the diagnostic criteria for persistent depressive disorder and recognize the clinical presentation of this disorder.
• Implement evidence-based treatments for individuals with persistent depressive disorder.
• Apply effective strategies to improve care coordination among interprofessional team members to facilitate positive outcomes for individuals with persistent depressive disorder.

Introduction

Persistent depressive disorder (PDD) was a new diagnosis in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) in 2013 that combined dysthymia and chronic major depressive disorder.[1] The classification of depressive symptoms has a complicated history dating back to the description of melancholic temperament by Hippocrates.[2][3] According to the DSM-5, persistent depressive disorder is characterized by a depressed mood that occurs for most of the day, for more days than not, for at least 2 years, or at least 1 year for children and adolescents. Major depression may precede PDD, and major depressive episodes may occur during PDD, which is known as double depression. PDD may begin early in life, and depressive symptoms may wax and wane but never fully resolve.

Etiology

Biopsychosocial conceptualizations postulate that depression is a multifactorial disease state caused by biological, social, psychological, and spiritual factors.[4] Risk factors for persistent depressive disorder may include genetics, epigenetics, prior mental illness, neuroticism, high anxiety states, sense of self-worth, psychological health, trauma, life stressors, and social determinants of health.[5] However, depressive symptoms are heterogeneous, and there are few studies investigating participants who were healthy at baseline. Studies of the onset and recurrence of depressive symptoms are scarce.[6] 

Antecedents of chronic depression include greater childhood adversity and maltreatment, childhood loss of a parent, higher rates of chronic depression in relatives, and earlier onset of depression.[1] There are high rates of comorbidity between PDD and borderline personality disorder, which is a risk factor for PDD, suggesting that the disorders may share etiological factors such as genetics, temperamental vulnerability, interpersonal stress, or childhood maltreatment. During their lifetimes, individuals with PDD experience a higher number of traumatic events.[7]

Results from one PDD study showed that depressed patients did not show deficits in decoding the affective states of others but may have difficulties in managing another person's negative emotional state. Individuals with PDD may be hypersensitive, feel overwhelmed by emotional situations, and develop empathic distress and empathic concern. Empathic distress was correlated with depression severity. Patients with PDD reported significantly more interpersonal problems and more childhood maltreatment, including increased levels of physical abuse, emotional abuse, emotional neglect, and total childhood maltreatment than healthy controls.[8] Interpersonal problems may lead to lower perceived social support, weaker social ties, and prolonged loneliness.[9]

Epidemiology

PDD was a new diagnosis in the DSM-5 in 2013 that combined dysthymia and chronic major depressive disorder.[1] Due to its relative newness as a diagnostic category, the epidemiology of PDD has not been well-studied. The DSM-5 Text Revision (DSM-5-TR) estimated the 12-month prevalence for dysthymia to be approximately 0.5% and 1.5% for chronic major depressive disorder. 

Results from a study of 3720 patients in Zurich found the prevalence was 15.2% for PDD with persistent major depressive episodes, 3.3% for PDD with pure dysthymia, and 28.2% for major depressive disorder.[10] According to the DSM-5-TR, the 12-month prevalence of major depressive disorder in the United States is approximately 7%, with a higher prevalence in women and steeper rates in youth than in older groups. The prevalence of major depressive disorder may vary 8- to 9-fold globally. Estimates of depression may be low in older adults due to the misattribution of depressive symptoms to physical disorders that increase with age.[11]

Pathophysiology

The pathophysiology of persistent depressive disorder is unknown. No studies of PDD exist, and older studies of dysthymia and chronic major depressive disorder have not been replicated.[1] Early research implicated serotonergic abnormalities, immune system dysregulation, neuroendocrine alterations, and sleep alterations. Only a few gene studies are available, flawed by the small study sizes and the absence of replication attempts and genome-wide approaches. Brain imaging has not demonstrated any firm conclusions about brain structure or neural network function in PDD, although the prefrontal cortex, anterior cingulate, amygdala, and hippocampus have been implicated.[1][12][13][14][15][16] Polysomnographic abnormalities may exist in PDD.

History and Physical

History 

PDD is often overlooked. In diagnoses, obtain a careful history and conduct a mental status examination. Assessing risks of harm to oneself or others and considering the influence of substance use are critical components of this assessment, as those with PDD have a higher risk of suicide. Collateral information from family members or close contacts is helpful. The primary objectives are to eliminate the possibility of other medical or psychiatric conditions and confirm the diagnosis based on the DSM-5-TR.

The following are essential elements of the history:

• History of present illness: Take a chronology of symptom presentation and predisposing, precipitating, and perpetuating factors, particularly mood, sleep, appetite, energy, self-esteem, concentration, decision-making capacity, and hopelessness. Review other psychiatric symptoms and comorbid diagnoses, especially if acute depressive episodes are preceded or followed by low-grade depression. Obtain a relevant negative history that could help differentiate PDD from other medical or psychiatric conditions. Using a screening tool, such as the one-question persistent depression screener, in conjunction with other depression screening instruments, can be a way to detect PDD.[17][18]
• Past psychiatric history: Include previous manic or depressive episodes, hospitalizations, treatments (including electroconvulsive therapy), adherence to treatments, the effects and adverse effects of medication, and any history of suicidality (ideas, plans, or attempts, including details), self-injury, or aggressive ideas or behavior. A life chart or timeline may help elucidate a pattern of depressive symptoms.
• Substance use history: Ask about the use of tobacco, alcohol, cannabis, or other substances.
• Medical history: Include medical illnesses, allergies, treatments, surgeries, parity, and other relevant health information, such as neurological conditions and sleep issues. Ask about diagnoses such as Parkinson disease, multiple sclerosis, syphilis, human immunodeficiency virus/acquired immunodeficiency syndrome, brain lesions, heavy metal toxicity, delirium, and metabolic or endocrine disorders.
• Medications: Ask about all medications and their indications.
• Family history: Include a family history of psychiatric illness, treatment and response to treatment, and history of suicidal or aggressive behaviors in biological relatives.
• Personal and social history: Language preferences, life circumstances, relationships, children, employment history, cultural views on psychiatric illness, stressors, trauma history, access to weapons, and legal concerns are important.
• Developmental history: Ask about any complications during childbirth, early development, history of trauma and abuse (including head trauma), and education.

Physical Examination

The physical examination should be performed with sensitivity to any trauma history. Vital signs such as blood pressure and heart rate are crucial in identifying underlying health issues. A comprehensive examination covers the neurological, cardiovascular, and respiratory systems. A dermatological examination helps detect signs of substance use or skin infections.

Mental Status Examination

ThemMental status examination (MSE) for PDD should include the following:

1. Appearance and behavior: Patients may present with disheveled attire, reflecting a lack of self-care. Assess for psychomotor retardation. Patient responses can vary from being cooperative to being withdrawn.
2. Speech: Assess for rate and tone.
3. Mood and affect: Individuals may describe their mood as depressed, sad, or "down in the dumps." Affect can be constricted.
4. Thought content: Assess for hallucinations and delusions.
5. Thought process: Inferred from the patient's speech. Is the patient clear and coherent?
6. Risk: Assess current suicidality (ideas, plans, access to weapons), self-injury (ideas or behaviors), and aggressive ideas or behaviors.
7. Cognition: Assess for orientation to person, place, and date.
8. Insight and judgment: Insight varies, with some patients partially aware of their condition while others lack insight. Judgment may be impaired, affecting the ability to make decisions.

No laboratory or radiologic studies currently exist for diagnosing PDD.

Diagnostic criteria for persistent depressive disorder

According to the DSM-5-TR, the following are the diagnostic criteria for persistent depressive disorder:

A. Depressed mood most of the day, more days than not, for at least 2 years.

B. At least 2 of the following 6 symptoms:

1. Poor appetite or overeating
2. Insomnia or hypersomnia
3. Low energy or fatigue
4. Low self-esteem
5. Poor concentration or difficulty making decisions
6. Feelings of hopelessness

C. During a 2-year period (1 year for children or adolescents), the individual has never been without the symptoms in Criteria A and B for more than 2 months at a time.

D. Criteria for a major depressive disorder may be continuously present for 2 years.

E. There has never been a manic or hypomanic episode.

F. The disturbance is not better explained by a schizophrenia spectrum or other psychotic disorder.

G. The symptoms are not attributable to the physiological effects of a substance or another medical condition.

H. The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.

A patient may meet the criteria for PDD and major depressive disorder at the same time, in which case a separate diagnosis of major depressive disorder should be made. The DSM-5-TR identifies specifiers to describe if the PDD is with a pure dysthymic syndrome or with a persistent major depressive episode, with anxious distress or atypical features, in partial or full remission, early onset or late onset, and severity (mild, moderate, or severe).[19] Dysthymia is maintained as a diagnosis in the International Classification of Diseases, 11th Revision.

Evaluation

A thorough assessment of patients presenting with mental health symptoms involves ruling out medical and biological causes of symptomatology. While routine laboratory screening of an otherwise healthy patient with symptoms of depression is of questionable diagnostic value, the following laboratory tests are commonly ordered to support medical decision-making: complete blood count, comprehensive metabolic panel, urine pregnancy test, urine toxicology screen, human immunodeficiency virus testing, rapid plasma reagin, vitamin B12, folate, and a thyroid panel. Symptoms and patient history guide additional testing.[20][21][22] 

Treatment / Management

Treatment success in PDD may be lower due to delays in diagnoses (and starting treatment), patient hopelessness, and inadequate treatment duration. Individuals with PDD may have histories of adverse childhood events, which are risk factors for chronic, early-onset depression; those with trauma histories may have better success with targeted therapies such as the cognitive behavioral analysis system of psychotherapy. Previous studies of psychotherapy for dysthymia showing less efficacy may be flawed by the low number of sessions provided. Studies of patients with chronic depression have shown better outcomes with longer duration of psychotherapy and higher numbers of sessions.[1][23] 

There is little research on the efficacy of medication or psychotherapy in PDD. One 2014 meta-analysis of studies of patients with pure dysthymia, chronic major depressive symptoms, and various forms of chronic major depression demonstrated that fluoxetine, paroxetine, sertraline, moclobemide (not approved for use in the United States), imipramine, ritanserin (not approved for use in the United States), amisulpride (only available in intravenous solution), and acetyl-l-carnitine (a dietary supplement) were more effective than placebo. Interpersonal psychotherapy (IPT) alone was less effective than IPT with medication. The studies of cognitive behavioral analysis system of psychotherapy with medication were inconsistent. There was insufficient evidence for several treatments, such as mirtazapine, venlafaxine, and psychodynamic psychotherapies.[24] Although there was not a clear benefit for combination treatment, the use of medication and psychotherapy together resulted in higher response rates and improved functioning.[1][25][26][27][28][29][30][31]

New models of treatment are under consideration for PDD, taking into consideration not only symptom modification but also improving mentalization capacity, developing empathy, increasing motivation, overcoming avoidance, social skills, healing trauma, addressing hopelessness and helplessness, and reducing comorbidities.[1] One case study showed the efficacy of the mood stabilizer lamotrigine, with remission of symptoms for over 2 years.[32] The American Association of Child and Adolescent Psychiatrists Clinical Practice Guideline suggests cognitive behavioral therapy or interpersonal psychotherapy as treatment for persistent depressive disorder. There was insufficient evidence available about the benefits or harms of selective serotonin reuptake inhibitors for PDD in children and adolescents.[33] 

Differential Diagnosis

According to the DMS-5-TR, the differential diagnoses for PDD are:

• Major depressive disorder (MDD): If the criteria are met for major depressive disorder during the time period for PDD, the additional diagnosis of MDD should be made.
• Other specified depressive disorder: There may be individuals who do not meet the criteria for either PDD or MDD but do have depressive symptoms lasting more than 2 years.
• Bipolar I and bipolar II disorders: A history of a manic or hypomanic episode excludes a diagnosis of PDD, and the individual should be assessed for bipolar I disorder or bipolar II disorder.
• Cyclothymia: If an individual has hypomanic symptoms that do not meet the criteria for a hypomanic episode and has a depressed mood for at least 2 years, the appropriate diagnosis would be cyclothymia.
• Psychotic disorders: Depressive symptoms that occur only during the course of a psychotic disorder would not warrant a diagnosis of PDD.
• Depressive or bipolar and related disorder due to another medical condition: This is the proper diagnosis if an individual's depressive symptoms are attributable to another medical condition, for example, multiple sclerosis.
• Substance/medication-induced depressive or bipolar and related disorder: If a substance such as a drug of abuse, a medication, or a toxin is judged to be the cause of the depressive symptoms.
• Personality disorders: These are characterized by enduring patterns of inner experience and behavior and commonly co-occur with PDD, in which case both can be diagnosed.

Pertinent Studies and Ongoing Trials

There are several areas for additional research:

• Further validation of the diagnosis of persistent depressive disorder
• Preferential use of medication, psychotherapy, or combination therapy
• Treatment effect modifiers such as family characteristics
• Effects of other psychotherapies, such as psychodynamic psychotherapy, attachment-based therapy, or family therapy
• Use of antidepressant medications or other psychotropic medications such as ketamine
• Use of interventional treatments such as transcranial magnetic stimulation or electroconvulsive therapy
• Use of lifestyle interventions such as exercise
• Effectiveness of treatments in minoritized populations
• Effectiveness of treatments in populations with developmental disorders
• Integrating mental health, medical treatment

  • For example, results from one study found high rates of persistent depressive disorder and major depression among patients undergoing human immunodeficiency virus testing.[33][34]

Prognosis

Even before the COVID-19 pandemic, depressive and anxiety disorders featured as leading causes of burden globally, despite the existence of intervention strategies that can reduce their effects.[35][36] The prognosis of PDD is similar, if not worse, than that of major depressive disorder. Outcomes of a 10-year study suggest that persistent depressive disorder is independently associated with greater severity of depression, anxiety, and somatic symptoms in individuals with major depressive disorder in comparison to individuals with major depressive disorder without PDD.[37] 

Complications

Persistent depressive disorder (PDD) negatively affects social and occupational functioning in varying ways, which can be as great or greater than a major depressive disorder. PDD is associated with an increased risk of suicidal outcomes. The symptoms of PDD are much less likely to fully resolve in a given period. Individuals with PDD are at higher risk of personality disorders and substance use disorders. Significant associations were found in inpatients with PDD between childhood emotional abuse and suicidal behaviors (including suicide attempts).[38] 

In one study, results showed that the suicide risk in those with sleep disorders was 1.429 times higher than in those with no sleep disorders, and people with PDD exhibited a 7.195 times higher risk of suicide compared with those without PDD. Those with sleep disorders and PDD exhibited a 1.174 times higher risk of suicide compared to those with no sleep disorders.[39]   

Consultations

Addiction, geriatric, and medical consultations are among the most common in PDD. 

Deterrence and Patient Education

Patient education is crucial in individuals with PDD. An informed patient is more likely to understand their diagnosis and treatment and have better treatment compliance.  

Pearls and Other Issues

Key considerations regarding PDD include:

• PDD is often overlooked.
• Assessing risks of harm to oneself or others and considering the influence of any substance use are critical components of this assessment, as people with PDD have a higher risk of suicide.
• Treatment success in persistent depressive disorder may be lower due to delays in diagnosing the disorder and starting treatment, patient hopelessness, and inadequate treatment duration.
• Individuals with PDD may have histories of adverse childhood events, which are risk factors for chronic, early-onset depression.
• Individuals with trauma histories may have better success with targeted therapies such as the cognitive behavioral analysis system of psychotherapy.
• Fluoxetine, paroxetine, sertraline, moclobemide (not approved for use in the United States), imipramine, ritanserin (not approved for use in the United States), amisulpride (only available in intravenous solution), and acetyl-l-carnitine (a dietary supplement) were more effective than placebo in treating patients with pure dysthymia, chronic major depressive symptoms, and various forms of chronic major depression.
• In one case study, a patient with PDD had sustained improvement with lamotrigine.
• Medication and psychotherapy combined may result in higher response rates and improved functioning.

Enhancing Healthcare Team Outcomes

Providing patient-centered care for individuals with PDD requires an interdisciplinary approach. The healthcare team includes psychiatrists, primary care physicians, advanced practitioners, psychologists, nurses, pharmacists, vocational rehabilitation therapists, occupational therapists, and social workers. Healthcare professionals should understand the clinical aspects of PDD, including diagnosis, symptom management, and the complexities of psychopharmacological and psychotherapeutic treatments. This expertise is critical in interpreting psychiatric assessments, recognizing the range of symptoms, and understanding the challenges in managing PDD over the long term. 

Interprofessional collaboration is essential, with each team member contributing specialized knowledge and skills to optimize patient care. Effective communication within the team is critical to creating an environment where information is shared, concerns are addressed, and patient-centric strategies are developed. This coordination is vital for minimizing treatment errors, reducing delays in care, and enhancing patient safety, leading to improved outcomes and patient-centered care that prioritizes the recovery of individuals with PDD.[40] 

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Schramm E, Klein DN, Elsaesser M, Furukawa TA, Domschke K. Review of dysthymia and persistent depressive disorder: history, correlates, and clinical implications. Lancet Psychiatry. 2020 Sep;7(9):801-812. [PubMed: 32828168]

2.

Rhebergen D, Graham R. The re-labelling of dysthymic disorder to persistent depressive disorder in DSM-5: old wine in new bottles? Curr Opin Psychiatry. 2014 Jan;27(1):27-31. [PubMed: 24270481]

3.

Freeman HL. Historical and nosological aspects of dysthymia. Acta Psychiatr Scand Suppl. 1994;383:7-11. [PubMed: 7942068]

4.

Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000 Oct;157(10):1552-62. [PubMed: 11007705]

5.

Kendler KS, Gardner CO, Prescott CA. Toward a comprehensive developmental model for major depression in men. Am J Psychiatry. 2006 Jan;163(1):115-24. [PubMed: 16390898]

6.

Kennis M, Gerritsen L, van Dalen M, Williams A, Cuijpers P, Bockting C. Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry. 2020 Feb;25(2):321-338. [PMC free article: PMC6974432] [PubMed: 31745238]

7.

Konvalin F, Grosse-Wentrup F, Nenov-Matt T, Fischer K, Barton BB, Goerigk S, Brakemeier EL, Musil R, Jobst A, Padberg F, Reinhard MA. Borderline Personality Features in Patients With Persistent Depressive Disorder and Their Effect on CBASP Outcome. Front Psychiatry. 2021;12:608271. [PMC free article: PMC8006327] [PubMed: 33790813]

8.

Struck N, Gärtner T, Kircher T, Brakemeier EL. Social Cognition and Interpersonal Problems in Persistent Depressive Disorder vs. Episodic Depression: The Role of Childhood Maltreatment. Front Psychiatry. 2020;11:608795. [PMC free article: PMC7873909] [PubMed: 33584373]

9.

Nenov-Matt T, Barton BB, Dewald-Kaufmann J, Goerigk S, Rek S, Zentz K, Musil R, Jobst A, Padberg F, Reinhard MA. Loneliness, Social Isolation and Their Difference: A Cross-Diagnostic Study in Persistent Depressive Disorder and Borderline Personality Disorder. Front Psychiatry. 2020;11:608476. [PMC free article: PMC7773662] [PubMed: 33391058]

10.

Vandeleur CL, Fassassi S, Castelao E, Glaus J, Strippoli MF, Lasserre AM, Rudaz D, Gebreab S, Pistis G, Aubry JM, Angst J, Preisig M. Prevalence and correlates of DSM-5 major depressive and related disorders in the community. Psychiatry Res. 2017 Apr;250:50-58. [PubMed: 28142066]

11.

Kessler RC, Birnbaum H, Bromet E, Hwang I, Sampson N, Shahly V. Age differences in major depression: results from the National Comorbidity Survey Replication (NCS-R). Psychol Med. 2010 Feb;40(2):225-37. [PMC free article: PMC2813515] [PubMed: 19531277]

12.

Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997 Jul;54(7):597-606. [PubMed: 9236543]

13.

Thase ME. Molecules that mediate mood. N Engl J Med. 2007 Dec 06;357(23):2400-2. [PubMed: 18057345]

14.

Nutt DJ, Baldwin DS, Clayton AH, Elgie R, Lecrubier Y, Montejo AL, Papakostas GI, Souery D, Trivedi MH, Tylee A. Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry. 2006;67 Suppl 6:46-9. [PubMed: 16848678]

15.

Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA, Berman RM, Charney DS, Krystal JH. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 1999 Nov;56(11):1043-7. [PubMed: 10565505]

16.

Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ, Hulshoff Pol HE, Kahn RS. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp. 2009 Nov;30(11):3719-35. [PMC free article: PMC6871089] [PubMed: 19441021]

17.

Kroenke K, Spitzer RL, Williams JB, Löwe B. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. Gen Hosp Psychiatry. 2010 Jul-Aug;32(4):345-59. [PubMed: 20633738]

18.

Brinkmann E, Glanert S, Hüppe M, Moncada Garay AS, Tschepe S, Schweiger U, Klein JP. Psychometric evaluation of a screening question for persistent depressive disorder. BMC Psychiatry. 2019 Apr 23;19(1):119. [PMC free article: PMC6480904] [PubMed: 31014295]

19.

Uher R, Payne JL, Pavlova B, Perlis RH. Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV. Depress Anxiety. 2014 Jun;31(6):459-71. [PubMed: 24272961]

20.

Korn CS, Currier GW, Henderson SO. "Medical clearance" of psychiatric patients without medical complaints in the Emergency Department. J Emerg Med. 2000 Feb;18(2):173-6. [PubMed: 10699517]

21.

Conigliaro A, Benabbas R, Schnitzer E, Janairo MP, Sinert R. Protocolized Laboratory Screening for the Medical Clearance of Psychiatric Patients in the Emergency Department: A Systematic Review. Acad Emerg Med. 2018 May;25(5):566-576. [PubMed: 29266617]

22.

Ordas DM, Labbate LA. Routine screening of thyroid function in patients hospitalized for major depression or dysthymia? Ann Clin Psychiatry. 1995 Dec;7(4):161-5. [PubMed: 8721889]

23.

Nübel J, Guhn A, Müllender S, Le HD, Cohrdes C, Köhler S. Persistent depressive disorder across the adult lifespan: results from clinical and population-based surveys in Germany. BMC Psychiatry. 2020 Feb 10;20(1):58. [PMC free article: PMC7011512] [PubMed: 32041560]

24.

Kriston L, von Wolff A, Westphal A, Hölzel LP, Härter M. Efficacy and acceptability of acute treatments for persistent depressive disorder: a network meta-analysis. Depress Anxiety. 2014 Aug;31(8):621-30. [PubMed: 24448972]

25.

Carta MG, Paribello P, Nardi AE, Preti A. Current pharmacotherapeutic approaches for dysthymic disorder and persistent depressive disorder. Expert Opin Pharmacother. 2019 Oct;20(14):1743-1754. [PubMed: 31290333]

26.

Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. J Clin Psychiatry. 2009 Sep;70(9):1219-29. [PubMed: 19818243]

27.

Cuijpers P, van Straten A, Warmerdam L, Andersson G. Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: a meta-analysis. Depress Anxiety. 2009;26(3):279-88. [PubMed: 19031487]

28.

Linde K, Kriston L, Rücker G, Jamil S, Schumann I, Meissner K, Sigterman K, Schneider A. Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. Ann Fam Med. 2015 Jan-Feb;13(1):69-79. [PMC free article: PMC4291268] [PubMed: 25583895]

29.

Meister R, von Wolff A, Mohr H, Härter M, Nestoriuc Y, Hölzel L, Kriston L. Comparative Safety of Pharmacologic Treatments for Persistent Depressive Disorder: A Systematic Review and Network Meta-Analysis. PLoS One. 2016;11(5):e0153380. [PMC free article: PMC4871495] [PubMed: 27187783]

30.

Meister R, Jansen A, Härter M, Nestoriuc Y, Kriston L. Placebo and nocebo reactions in randomized trials of pharmacological treatments for persistent depressive disorder. A meta-regression analysis. J Affect Disord. 2017 Jun;215:288-298. [PubMed: 28363152]

31.

Furukawa TA, Efthimiou O, Weitz ES, Cipriani A, Keller MB, Kocsis JH, Klein DN, Michalak J, Salanti G, Cuijpers P, Schramm E. Cognitive-Behavioral Analysis System of Psychotherapy, Drug, or Their Combination for Persistent Depressive Disorder: Personalizing the Treatment Choice Using Individual Participant Data Network Metaregression. Psychother Psychosom. 2018;87(3):140-153. [PubMed: 29847831]

32.

Matsuzaka Y, Urashima K, Sakai S, Morimoto Y, Kanegae S, Kinoshita H, Imamura A, Ozawa H. The effectiveness of lamotrigine for persistent depressive disorder: A case report. Neuropsychopharmacol Rep. 2022 Mar;42(1):120-123. [PMC free article: PMC8919124] [PubMed: 34989158]

33.

Walter HJ, Abright AR, Bukstein OG, Diamond J, Keable H, Ripperger-Suhler J, Rockhill C. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent Depressive Disorders. J Am Acad Child Adolesc Psychiatry. 2023 May;62(5):479-502. [PubMed: 36273673]

34.

Kagee A, Saal W. Persistent depressive disorder among persons receiving an HIV test: an understudied phenomenon. AIDS Care. 2022 Dec;34(12):1530-1533. [PubMed: 35914113]

35.

COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021 Nov 06;398(10312):1700-1712. [PMC free article: PMC8500697] [PubMed: 34634250]

36.

Katon W, Ciechanowski P. Impact of major depression on chronic medical illness. J Psychosom Res. 2002 Oct;53(4):859-63. [PubMed: 12377294]

37.

Hung CI, Liu CY, Yang CH. Persistent depressive disorder has long-term negative impacts on depression, anxiety, and somatic symptoms at 10-year follow-up among patients with major depressive disorder. J Affect Disord. 2019 Jan 15;243:255-261. [PubMed: 30248637]

38.

Wolf J, Reinhard MA, Goerigk S, Barton BB, Burkhardt G, Tang J, Eder J, Amann BL, Bertsch K, Jobst A, Musil R, Padberg F. Suicidal behaviors and adverse childhood experiences: A cross-diagnostic study in persistent depressive disorder and borderline personality disorder. Psychiatry Res. 2023 Dec;330:115562. [PubMed: 37918208]

39.

Hsiao SH, Cheng CC, Lin IJ, Yu CP, Huang YC, Huang SH, Sun CA, Fann LY, Sheu MY, Chien WC. Persistent Depressive Disorder-Related Effect of Sleep Disorder on the Highest Risk of Suicide in Taiwan, 2000-2015. Int J Environ Res Public Health. 2022 Oct 13;19(20) [PMC free article: PMC9603005] [PubMed: 36293761]

40.

Zeiss AM, Karlin BE. Integrating mental health and primary care services in the Department of Veterans Affairs health care system. J Clin Psychol Med Settings. 2008 Mar;15(1):73-8. [PubMed: 19104957]

Disclosure: Raj Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Sunny Aslam declares no relevant financial relationships with ineligible companies.

Disclosure: Gregory Rose declares no relevant financial relationships with ineligible companies.